https://www.thebodypro.com/category/prep-hiv-pre-exposure-prophylasxis/tag/women

The Latest

Mexico City's Downtown At Twilight

IAS 2019: What to Expect in HIV Science

Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

Fleur De Kine

New Campaign, Toolkit Gets Providers PrEP'd for Women

New York City aims to expand PrEP and PEP access by educating more clinicians that serve women.

This Week in HIV Research: Fentanyl Smooths the Path for HIV

April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.

This Week in HIV Research: Prevention and Treatment in the Real World

Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.

This Week in HIV Research: A Long-Acting Popularity Contest

The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.

This Week in HIV Research: Transgender Women in the Spotlight

Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?

This Week in HIV Research: The PrEP Sex/Race Gap

PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.

This Week in HIV Research: Gender Disparities Among the Formerly Incarcerated

Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.

Pregnant woman with pill bottle

Making Clinical Trials of PrEP More Inclusive of Women, No Matter Their Pregnancy Status

Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?

Truvada pills

On-Demand PrEP Is Great. Now, What About Women?

What do on-demand PrEP advances seen in men mean for a developing a biomedical prevention agenda for women?